Description :
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients . Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer .
Check the DISCOUNT on this report @ http :// www . orbisresearch . com / contacts / discount / 214475 .
The global Chemotherapy-induced Nausea and Vomiting market was valued at $ 1,663 million in 2015 , and is estimated to reach $ 2 , 659 million by 2022 , registering a CAGR of 7.1 % during the forecast period . At present , pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies . Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market . It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast , lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients .
The global CINV market is segmented into patient pool type and geography . The patient pool type is segmented into namely Aloxi ( palonosetron ), Kytril Generic ( Granisetron ), Emend ( aprepitant ), Netupitant-Palonosetron FDC and Others . Among the segments , the Netupitant Palonosetron market is expected to witness the fastest growth , globally during the forecast period 2016-2022 .
Based on geography , the global CINV market is segmented into North America , Europe , Asia-Pacific , and LAMEA . North America held the largest share ( nearly half ) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy , introduction of novel delivery methods to improve patient compliance . However , Asian region is expected to grow at a fastest CAGR during the forecast period , owing to large CINV patient pool and huge demand for the Netupitant – Palonosetron from these patients . Netupitant - Palonosetron is one of the first forms of fixed dose combination , which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future .
Purchase a copy of this report @ http :// www . orbisresearch . com / contact / purchase / 214475 .
KEY BENEFITS The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets . The study provides analysis of key market dynamics , which influence the adoption of CINV drugs The report provides a quantitative analysis for the period of 2014 – 2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry .
2